Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation

International Journal of Pharmaceutics

Volumn 511, Issue 1, 2016, Pages 648-658

  Rochani, Ankit K ^a   Balasubramanian, Sivakumar ^a   Ravindran Girija, Aswathy ^a   Raveendran, Sreejith ^a   Borah, Ankita ^a   Nagaoka, Yutaka ^a   Nakajima, Yoshikata ^a   Maekawa, Toru ^a   Kumar, D Sakthi ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

17AAG; Cancer chemotherapy; Hsp90 inhibitor; Nano formulation; Nanotechnology

Indexed keywords

17 N ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; FERROUS SULFATE; HEAT SHOCK PROTEIN 90 INHIBITOR; MAGNETIC NANOPARTICLE; NANOCARRIER; POLYGLACTIN; UNCLASSIFIED DRUG; FERRIC ION; FERRIC OXIDE; HEAT SHOCK PROTEIN 90; NANOPARTICLE; POLYMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER THERAPY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTHERMIA; IN VITRO STUDY; MAGNETIC HYPERTHERMIA; NANOTECHNOLOGY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOUSE; PANCREATIC NEOPLASMS; PHYSIOLOGY; PROCEDURES; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMPOUNDING; FERRIC COMPOUNDS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NANOPARTICLES; PANCREATIC NEOPLASMS; POLYMERS; PROTEIN STRUCTURE, SECONDARY;

EID: 84979743286     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.07.048     Document Type: Article

References (46)

1. Acquaviva, J., He, S., Sang, J., Smith, D.L., Sequeira, M., Zhang, C., Bates, R.C., Proia, D.A., mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Mol. Cancer Res. 12 (2014), 703–713.
2. Akbarzadeh, A., Zarghami, N., Mikaeili, H., Asgari, D., Goganian, A.M., Khiabani, H.K., Samiei, M., Davaran, S., Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol. Sci. Appl. 5 (2012), 13–25.
3. Ali, M.M., Roe, S.M., Vaughan, C.K., Meyer, P., Panaretou, B., Piper, P.W., Prodromou, C., Pearl, L.H., Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440 (2006), 1013–1017.
4. Alvarez-Berrios, M.P., Castillo, A., Mendez, J., Soto, O., Rinaldi, C., Torres-Lugo, M., Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int. J. Nanomed. 8 (2013), 1003–1013.
5. https://clinicaltrials.gov/ct2/show/NCT00178763, 2015. Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer (FR-WB-TT).
6. Aravind, A., Nair, R., Raveendran, S., Veeranarayanan, S., Nagaoka, Y., Fukuda, T., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Kumar, D.S., Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy. J. Magn. Magn. Mater. 344 (2013), 116–123.
7. Arora, G., Malik, K., Singh, I., Arora, S., Rana, V., Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using Salvia plebeian gum. J. Adv. Pharm. Technol. Res. 2 (2011), 163–169.
8. Balasubramanian, S., Girija, A.R., Nagaoka, Y., Iwai, S., Suzuki, M., Kizhikkilot, V., Yoshida, Y., Maekawa, T., Nair, S.D., Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int. J. Nanomed. 9 (2014), 437–459.
9. Balasubramanian, S., Girija, A.R., Nagaoka, Y., Fukuda, T., Iwai, S., Kizhikkilot, V., Kato, K., Maekawa, T., Nair, S.D., An ‘all in one' approach for simultaneous chemotherapeutic, photothermal and magnetic hyperthermia mediated by hybrid magnetic nanoparticles. RSC Adv. 5 (2015), 25066–25078.
10. Chandran, T., Katragadda, U., Teng, Q., Tan, C., Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Int. J. Pharm. 392 (2010), 170–177.
11. Cho, H., Kwon, G.S., Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery. J. Drug Target. 22 (2014), 669–677.
12. Dash, S., Murthy, P.N., Nath, L., Chowdhury, P., Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm. 67 (2010), 217–223.
13. Davaran, S., Alimirzalu, S., Nejati-Koshki, K., Nasrabadi, H.T., Akbarzadeh, A., Khandaghi, A.A., Abbasian, M., Alimohammadi, S., Physicochemical characteristics of Fe3O4 magnetic nanocomposites based on Poly(N-isopropylacrylamide) for anti-cancer drug delivery. Asian Pac. J. Cancer Prev. 15 (2014), 49–54.
14. Glover, A.L., Bennett, J.B., Pritchett, J.S., Nikles, S.M., Nikles, D.E., Nikles, J.A., Brazel, C.S., Magnetic heating of iron oxide nanoparticles and magnetic micelles for cancer therapy. IEEE Trans. Magn. 49 (2013), 231–235.
15. Hasenstein, J.R., Shin, H.C., Kasmerchak, K., Buehler, D., Kwon, G.S., Kozak, K.R., Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol. Cancer Ther. 11 (2012), 2233–2242.
16. Hines, D.J., Kaplan, D.L., Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit. Rev. Ther. Drug Carrier Syst. 30 (2013), 257–276.
17. Ishikawa, T., Kokura, S., Sakamoto, N., Ando, T., Imamoto, E., Hattori, T., Oyamada, H., Yoshinami, N., Sakamoto, M., Kitagawa, K., Okumura, Y., Yoshida, N., Kamada, K., Katada, K., Uchiyama, K., Handa, O., Takagi, T., Yasuda, H., Sakagami, J., Konishi, H., Yagi, N., Naito, Y., Yoshikawa, T., Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int. J. Hyperthermia 28 (2012), 597–604.
18. Ito, A., Saito, H., Mitobe, K., Minamiya, Y., Takahashi, N., Maruyama, K., Motoyama, S., Katayose, Y., Ogawa, J., Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature. Cancer Sci. 100 (2009), 558–564.
19. Jia, Y., Yuan, M., Yuan, H., Huang, X., Sui, X., Cui, X., Tang, F., Peng, J., Chen, J., Lu, S., Xu, W., Zhang, L., Guo, Q., Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int. J. Nanomed. 7 (2012), 1697–1708.
20. Katragadda, U., Teng, Q., Rayaprolu, B.M., Chandran, T., Tan, C., Multi-drug delivery to tumor cells via micellar nanocarriers. Int. J. Pharm. 419 (2011), 281–286.
21. Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15 (1983), 25–35.
22. Lacerda, L., Parize, A.L., Favere, V., Laranjeira, M.C., Stulzer, H.K., Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin. Mater. Sci. Eng. C 39 (2014), 161–167.
23. Li, F., Sun, J., Zhu, H., Wen, X., Lin, C., Shi, D., Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin. Colloids Surf. B 88 (2011), 58–62.
24. Li, Y., Zhang, T., Schwartz, S.J., Sun, D., Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Nutr. Cancer 63 (2011), 1151–1159.
25. Lu, X., Xiao, L., Wang, L., Ruden, D.M., Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 83 (2012), 995–1004.
26. Modi, S., Stopeck, A.T., Gordon, M.S., Mendelson, D., Solit, D.B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., Cropp, G.F., Johnson, R.G., Hannah, A.L., Hudis, C.A., Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 25 (2007), 5410–5417.
27. Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M.E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A.L., Hudis, C., HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17 (2011), 5132–5139.
28. Mohapatra, S., Pal, D., Ghosh, S.K., Pramanik, P., Design of superparamagnetic iron oxide nanoparticle for purification of recombinant proteins. J. Nanosci. Nanotechnol. 7 (2007), 3193–3199.
29. Mukherjee, B., Santra, K., Pattnaik, G., Ghosh, S., Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int. J. Nanomed. 3 (2008), 487–496.
30. Murakami, H., Kobayashi, M., Takeuchi, H., Kawashima, Y., Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187 (1999), 143–152.
31. Neckers, L., Workman, P., Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 18 (2012), 64–76.
32. Ogden, J., Tate, J., Strawbridge, R., Ivkov, R., Hoopes, P., Comparison of iron oxide nanoparticle and waterbath hyperthermia cytotoxicity. Proc. SPIE Int. Soc. Opt. Eng., 7181, 2009, 71810K.
33. Pradhan, R., Poudel, B.K., Choi, J.Y., Choi, I.S., Shin, B.S., Choi, H.G., Yong, C.S., Kim, J.O., Preparation and evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG)-loaded poly(lactic acid-co-glycolic acid) nanoparticles. Arch. Pharm. Res. 38 (2015), 734–741.
34. Pradhan, R., Ramasamy, T., Choi, J.Y., Kim, J.H., Poudel, B.K., Tak, J.W., Nukolova, N., Choi, H.G., Yong, C.S., Kim, J.O., Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin. Carbohydr. Polym. 123 (2015), 313–323.
35. Rahimi, M., Yousef, M., Cheng, Y., Meletis, E.I., Eberhart, R.C., Nguyen, K., Formulation and characterization of a covalently coated magnetic nanogel. J. Nanosci. Nanotechnol. 9 (2009), 4128–4134.
36. Ranjan, A.P., Mukerjee, A., Helson, L., Vishwanatha, J.K., Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J. Nanobiotechnol., 10, 2012, 38.
37. Rochani, A.K., Singh, M., Tatu, U., Heat shock protein 90 inhibitors as broad spectrum anti-infectives. Curr. Pharm. Des. 19 (2013), 377–386.
38. Rochani, A.K., Ravindran Girija, A., Borah, A., Maekawa, T., Sakthi Kumar, D., Heat-shock protein 90-targeted nano anticancer therapy. J. Pharm. Sci., 2015.
39. Saxena, V., Naguib, Y., Hussain, M.D., Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloids Surf. B 94 (2012), 274–280.
40. Sidera, K., Patsavoudi, E., HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat. Anticancer Drug Discov. 9 (2014), 1–20.
41. Sivakumar, B., Aswathy, R.G., Nagaoka, Y., Iwai, S., Venugopal, K., Kato, K., Yoshida, Y., Maekawa, T., Kumar, D.N.S., Aptamer conjugated theragnostic multifunctional magnetic nanoparticles as a nanoplatform for pancreatic cancer therapy. RSC Adv. 3 (2013), 20579–20598.
42. Sivakumar, B., Aswathy, R.G., Nagaoka, Y., Suzuki, M., Fukuda, T., Yoshida, Y., Maekawa, T., Sakthikumar, D.N., Multifunctional carboxymethyl cellulose-based magnetic nanovector as a theragnostic system for folate receptor targeted chemotherapy, imaging, and hyperthermia against cancer. Langmuir 29 (2013), 3453–3466.
43. Whitesell, L., Santagata, S., Mendillo, M.L., Lin, N.U., Proia, D.A., Lindquist, S., HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 18297–18302.
44. Xiong, M.P., Yanez, J.A., Kwon, G.S., Davies, N.M., Forrest, M.L., A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J. Pharm. Sci. 98 (2009), 1577–1586.
45. Yang, R., Tang, Q., Miao, F., An, Y., Li, M., Han, Y., Wang, X., Wang, J., Liu, P., Chen, R., Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice. Int. J. Nanomed. 10 (2015), 7345–7358.
46. Zhang, T., Li, Y., Zhu, Z., Gu, M., Newman, B., Sun, D., MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Mol. Pharm. 7 (2010), 1576–1584.